Labeling boundaries
Is PT-141 approved for men?
No. PT-141 is the peptide-market name commonly used for bremelanotide, and the FDA-approved bremelanotide product Vyleesi is labeled for acquired, generalized hypoactive sexual desire disorder in premenopausal women. The label states it is not indicated for men, postmenopausal women, or sexual-performance enhancement. That matters because men’s sexual-health symptoms often need a different evaluation path.
- Erectile dysfunction, low libido, low testosterone symptoms, depression, medication side effects, sleep apnea, vascular disease, and relationship stress should not be collapsed into one “PT-141 for men” answer.
- Any discussion outside the labeled Vyleesi population is off-label or compounded-product territory and should be framed as individualized clinician judgment, not a routine online purchase.
- Compounded medications, when used, are individualized prescriptions and are not FDA-approved finished drug products.